Bifunctional Immune-Linker Compounds for Targeted Antibody Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and infectious diseases lack effective methods to specifically target and enhance the immune response, with existing therapies facing challenges such as resistance and reduced efficacy, particularly in monoclonal antibody therapies.
Innovation Solution
Development of novel compounds that link an immune response to defined therapeutic targets by using carbohydrate molecules like rhamnose or alpha-Gal to bind with antibodies, creating multivalent linkers that enhance the immune response against cancer cells or pathogens, utilizing monoclonal antibodies and their fragments to recruit natural antibodies effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibody therapies are used to target cancer cells or pathogens, then specific immune response is enhanced, but resistance develops and therapeutic efficacy decreases
Solution Approach 1:
The patent combines multiple binding moieties (carbohydrate molecules like rhamnose or alpha-Gal and protein moieties like antibodies or antibody fragments) into a single bifunctional compound. This merging allows the compound to simultaneously engage both the patient's natural antibodies and the therapeutic target, creating a more robust and versatile immune response that can overcome resistance to single-approach therapies
Solution Approach 2:
The bifunctional compounds are designed with universal applicability by using carbohydrate molecules that can bind to pre-existing natural antibodies in all patients, while the protein moiety can be customized to target different cancer cells or pathogens. This multi-functionality allows a single compound design strategy to address multiple therapeutic indications and overcome diverse resistance mechanisms
2Adaptability or versatility
If existing immune response targeting methods are used, then some therapeutic effect is achieved, but the ability to specifically target and generate broad range of tumour associated antigens is limited
Solution Approach 1:
The compound is segmented into two distinct functional modules: a carbohydrate binding moiety (rhamnose or alpha-Gal) that interacts with natural antibodies, and a protein binding moiety (antibody or fragment) that targets the therapeutic antigen. This segmentation allows each module to be optimized independently while maintaining overall functionality, managing structural complexity through modular design
Solution Approach 2:
The bifunctional compound acts as an intermediary molecule that bridges the patient's natural immune system (natural antibodies) and the therapeutic target (cancer cells or pathogens). By introducing this intermediary, the patent enables the immune system to recognize and attack targets that would otherwise be invisible to natural antibodies, thereby enhancing targeting capability without requiring complete redesign of the immune response mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds optimize the recruitment of natural antibodies, enhancing the immune response against cancer cells and pathogens while maintaining target binding efficacy, addressing resistance and improving therapeutic outcomes.
Implementation Method 1
F represents rhamnose or a carbohydrate molecule capable of binding to a human anti-alpha-galactosyl antibody
Implementation Method 2
The human immune system continually surveys the body seeking foreign signals to identify potentially harmful pathogens or mutated human cells
Implementation Method 3
L represents a binding moiety selected from an antibody or antigen binding fragment thereof
Implementation Method 4
utilizing monoclonal antibodies and their fragments to recruit natural antibodies effectively
Implementation Method 5
creating multivalent linkers that enhance the immune response against cancer cells or pathogens
Implementation Method 6
The resultant effect of said immunity linker molecule is that the pre-existing immune response of the individual is diverted towards the target
Data Source
AI summary
The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of the compounds in treating cancer and infectious diseases, to compositions containing the compounds, processes for their preparation and to novel intermediates used in the process.